Endometrial cancer is the most common gynaecological cancer in western countries. The prevalence of EC is increasing at a rate of 1–2% every year. Advanced endometrial cancer has a 5-year survival rate of 59.6 percent for stage III disease and 28.6 percent for stage IV disease. pembrolizumab has been approved by the FDA for endometrial cancer, highlighting the need for new therapies to treat advanced, recurrent, metastatic endometrial cancer. The National Cancer Institute (NCI) and others are currently concentrating their efforts on developing scientifically sound targeted therapy and immunotherapy trials for specific endometrial cancer molecular characteristics. Our increased knowledge of the molecular aspects of endometrial cancer biology has paved the way for clinical research to develop novel targeted antineoplastic agents (everolimus, temsirolimus, gefitinib, erlotinib, trastuzumab, bevacizumab) as more effective and less toxic options.